 |
 |
BioPharm International Editor Hosts Interphex Keynote; MSNBC’s Chris Matthews Presents Feature Address Iselin, NJ, -- April 20, 2010— Laura Bush, editor in chief of BioPharm International, moderated the keynote panel discussion at Interphex 2010 today, held at the Jacob Javits Convention Center in New York City. The panel discussion addressed the impact of healthcare reform on the pharmaceutical industry.
The panel discussion followed a special presentation by Chris Matthews, the host of MSNBC’s “Hardball”, on the political power of the healthcare reform debate. The keynote panelists included Matthew Hudes, U.S. Managing Principal for Biotechnology in the Life Sciences & Health Care practice of Deloitte LLP; John Engel, Founding and Managing Partner of Engel & Novitt, LLP; and Michael Mawby, Chief Government Affairs Officer at NovoNordisk. The keynote panel discussion covered a range of questions, including whether the deal that PhRMA struck with the White House in June 2009 was good for the industry; whether the new payment advisory board created by the healthcare reform bill might strike down the non-interference clause in Medicare Part D; the impact of the biosimilars provisions of the bill on both innovator and generics firms, as well as likely pricing scenarios, Big Pharma strategies regarding biosimilars, and the effect of biosimilars on venture capital and innovation; the potential effects of comparative effectiveness studies, and lastly, how healthcare reform may affect biopharmaceutical and pharmaceutical manufacturing operations. Highlights of the panel discussion will be posted at www.biopharminternational.com/Interphex2010. In addition to presenting the keynote, BioPharm International magazine also co-hosted the new Main Stage, in collaboration with Pharmaceutical Technology magazine. At the Main Stage, located in the Interphex exhibit hall, the editors of BioPharm International and Pharmaceutical Technology conducted live, vidcast interviews with industry professionals on a range of topics related to the manufacture of both small-molecule and large-molecule pharmaceuticals. Key biotech topics included an analysis of the vaccine manufacturing response to the H1N1 outbreak, best practices for qualifying analytical methods, challenges in viral filtration, the economics of single-use technologies, strategies for increasing cell culture productivity, and automating fill–finish operations. To view these vidcasts, visit About BioPharm International:BioPharm International integrates the science and business of biopharmaceutical development and manufacturing. We provide practical, peer-reviewed technical solutions to enable biopharmaceutical professionals to perform their jobs more effectively. Now in its 23rd year, BioPharm is the longest-running peer-reviewed publication in its sector, with the largest US readership. BioPharm International is selectively abstracted or indexed in Biological Sciences Database (Cambridge Scientific Abstracts), Biotechnology and Bioengineering Database (Cambridge Scientific Abstracts), Biotechnology Citation Index (ISI/Thomson Scientific), Chemical Abstracts (CAS), Web of Science, Science Citation Index Expanded (ISI/Thomson Scientific). BioPharm International is published by Advanstar Communications. About Advanstar Communications:Advanstar Communications Inc. (www.advanstar.com) is a leading worldwide media company providing integrated marketing solutions for the Fashion, Life Sciences and Powersports industries. Advanstar serves business professionals and consumers in these industries with its portfolio of 147 events, 68 publications and directories, 267 electronic products and Web sites, as well as educational and direct marketing products and services. Market leading brands and a commitment to delivering innovative, quality products and services enables Advanstar to “Connect Our Customers With Theirs.” Advanstar has approximately 1,000 employees and currently operates from multiple offices in North America and Europe. About Interphex:
INTERPHEX is the world's most trusted source for leading‐edge technology, education, and sourcing of the products and services that drive scientific innovation for Life Sciences manufacturing from drug development to market – accelerating regulated products for patient care globally. INTERPHEX is the only Life Sciences event that represents a true cross‐section of the pharmaceutical and biopharmaceutical industries. Industry‐leading professionals worldwide make INTERPHEX the industry's annual focal point for driving change and efficiencies for the global pharmaceutical and biopharmaceutical market. The 2009 INTERPHEX event showcased more than 1,000 exhibiting companies, showcasing 1,600 product lines, and reached thousands of buyers. Over 13,000 industry professionals were in attendance. |
For more information, contact:
|
